The main modern methods of treatment of genitourinary menopausal syndrome

Symptoms of the genitourorinar menopausal syndrome appear simultaneously with vasomotor symptoms when menopause and even in perimenopause: soreness, itching and dryness in the vagina, dyspareunia, etc. This is due to the developmental atrophic changes in the urogenital tract, which sharply reduces the quality of life and is a risk factor for the development of recurrent infections of the genitourinary system. More than 65% of women in postmenopause without systemic menopausal hormonal therapy (MGT) suffer from manifestations of urogenital atrophy. This article discusses all modern methods of treating HUMS, describes various methods of treatment, their effectiveness, duration of application. As the first line of therapy, non -hormonal lubricants are recommended. With an average and severe degree of vulvovaginal atrophy and in the absence of contraindications, local intravaginal administration of estriol is used. The new promising methods of treatment with the State Unitary Enterprise are also described: Ospemicifen-oral, active selective selective modhertator of estrogen receptors (SERM), laser therapy, dehydroepiapianrosterone.

Conclusions. Genitouine menopausal syndrome – an underestimated common disease, but the frequency of use of local estrogens is low. Treatment should be continued for a long time to prevent relapse of the symptoms of Hums. Vaginal moisturizers can be used both in monotherapy and in combination with estriol.

1. Korotkikh N. V., Moshurov I. P., Samofalova O. V. et al. Complex therapy and prevention of vulvovaginal atrophy after special treatment in oncogynecological patients. Effective pharmacotherapy. 2024; 20 (19): 6–11. (In Russ.). DOI: 10.33978/2307-3586-2024-20-19-6-11

2. Balan V. E., Zarochentseva N.V., Kruchinina E. V., Tikhomirova E. V., Zhiltsova A.A. Tactics of managing women with genitourinary syndrome in perimenopause and postmenopause: a teaching aid. M., 2024. (In Russ.).

3. Tikhomirova E. V., Balan V. E., Kruchinina E. V., Balan P. V., Titchenko Yu.P., Lovygina T. V., Yatsyuk V. Ya. Possibilities of non-hormonal therapy for genitourinary syndrome. Effective pharmacotherapy. 2022; 18 (34): 6–13. (In Russ.).

4. Maltseva L. I., Gafarova E. A. Alternative therapy of genitourinary menopausal syndrome in women. Maltseva L. I., Gafarova E. A., Issues of practical colposcopy. Genital infections 2023; 1. (In Russ.).

5. BMS – Consensus statement Joan Pitkin; on behalf of the British Menopause Society medical advisory council Post Reproductive Health. 2018; 24 (3): 133–138.

6. Levine KB, Williams RE and Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008; 15: 661–666.

7. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J. Womens Health Gend Based Med. 2000; 9: S25–S 32. Review. Erratum in: J. Womens Health Gend Based Med. 2001; 10: 91.

8. Dennerstein L, Randolph J, Taffe J. et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril. 2002; 77: S 42–S 48.

9. Banks J, Batty GD, Nazroo J, and Steptoe A. The dynamics of ageing: evidence from the English Longitudinal Study of Ageing 2002–15 (Wave 7). ESRC & IFS: London, 2016.

10. Samsioe G, Jansson I, Mellstrom D. et al. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas. 1985; 7: 335–342.

11. Van Geelen JM, van de Weijer PH, Arnolds HT. Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50–75 years. Int Urogynecol J. Pelvic Floor Dysfunct. 2000; 11: 9–14.

12. Davila GW, Singh A, Karapanagiotou I. et al. Are women with urogenital atrophy symptomatic? Am. J. Obstet Gynecol 2003; 188: 382–388.

13. Notelovitz M, Funk S, Nanavati N. et al. Estradiol absorption from vaginal tablets in post-menopausal women. Obstet Gynecol. 2002; 99: 556–562.

14. Sturdee DW, Panay N and International Menopause Society Writing Group. Recommendations for the management of post-menopausal vaginal atrophy. Climacteric. 2010; 13: 509–522.

15. Portman DJ, Gass MLS, Kingsberg S. et al Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American Menopause Society Menopause. J. North Am Menopause Soc. 2014; 21: 1063–1068.

16. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000; 86: 32–38.

17. Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiolreleasing vaginal ring. Acta Obstet Gynecol Scand Suppl. 1993; 157: 1–26.

18. Zhu L, Lang JH, Feng RE. et al. Studyonestrogenreceptor around levator ani muscle for female stress urinary incontinence. Zhonghua Fu Chan Ke Za Zhi. 2004; 39: 655–657.

19. Sarrel PM. Sexuality and menopause. Obstet Gynecol. 1990; 75: 26S-30S; discussion 31S-35S.

20. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause. 2004; 11: 120–130.

21. Laan E, Everaerd W, Evers A. Assessment of female sexual arousal: response specificity and construct validity. Psychophysiology. 1995; 32: 476–485.

22. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996; 23: 259–263.

23. Petrukhin V.A., Tikhomirova E.V., Balan V.E., Kruchinina E.V., Titchenko Yu.P., Zhiltsova A.A., Yatsyuk V. Ya. Possibilities of non-hormonal therapy of genitourinary menopausal syndrome. Issues of practical colposcopy Genital infections. 2024; 1: 34–43. (In Russ.).

24. Biglia N, Peano E, Sgandurra P. et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26: 404–412.

25. Edwards D, Panay N. Treating vulvovaginal atrophy/ genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016; 19: 151–161.

26. Rosen AD, Rosen T. Study of condom integrity after brief exposure to over the counter vaginal preparations. South Med J. 1999; 92: 305–307.

27. NICE Menopause guideline: diagnosis and management [NG23]. November 2015.

28. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006; (4): CD001500. Review. Update in: Cochrane Database Syst Rev. 2016; 8: CD 001500. PubMed PMID: 17054136.

29. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009; 12: 91–105.

30. Ulrich LS, Naessen T, Elia D. et al. VAG-1748 trial investigators. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric. 2010; 13: 228–237.

31. Haspels AA, Luisi M, Kicovic PM. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas. 1981; 3: 321–327.

32. Constantine GD, Simon JA, Pickar JH. et al: REJOICE Study Group. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017; 24: 409–416.

33. Cardozo L, Bachmann G, McClish D. et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998; 92: 722–727.

34. Cardozo L, Lose G, McClish D. et al. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int Urogynecol J. Pelvic Floor Dysfunct. 2001; 12: 15–20.

35. Cardozo L, Lose G, McClish D. et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004; 83: 892–897.

36. Sant M, Galea P, Brincat MP. A comparative study between oestrogen replacement therapy, anticholinergic treatment and a combination of both in the management of detrusor instability in postmenopausal women. In: Book of Abstracts, The 10th World Congress on the menopause. Berlin, 2002.

37. Balan V. E., Tikhomirova E. V. Overactive bladder syndrome: A teaching aid for doctors. Moscow: GEOTAR-Media, 2024. (In Russ.).

38. NICE Urinary incontinence in women: management clinical guideline nice.org.uk/guidance/cg171 (2015).

39. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994; 83 (1): 12–18.

40. Henalla SM, Hutchins CJ, Robinson P. et al. Non-operative methods in the treatment of female genuine stress incontinence of urine. J. Obstet Gynaecol. 2009; 9: 222–225.

41. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) – results from an international survey. Climacteric. 2012; 15: 36–44.

42. Woyka J, Tanna N, Abernthy K. et al. A menopause service for women with breast cancer or at high risk from breast cancer. EJSO 2009; 35: 1226–1227.

43. Portman D, Palacios S, Nappi RE. et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014; 78: 91–98.

44. Constantine G, Graham S, Portman DJ. et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015; 18: 226–232.

45. Simon JA, Altomare C, Cort S. et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled Phase 2 and 3 trials. J. Womens Health (Larchmt) 2018; 27: 14–23.

46. Salvatore S, Pitsouni E, Del Deo. et al. Sexual function in women suffering from genitourinary syndrome of menopause treated with fractionated CO(2) laser. Sex Med Rev. 2017; 5: 486–494.

47. Gambacciani M, Levancini M, Russo E. et al. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric 2018; 21: 148–152.

48. Mikic AN. et al. 415 Use of vaginal erbium laser in treatment of vaginal relaxation syndrome and pelvic floor dysfunction. JISM. 2017; 14: S 126–S 127.

49. Labrie F, Archer DF, Koltun W. et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016; 23: 243–256.

50. Labrie F, Archer DF, Bouchard C. et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 2015; 81(1): 46–56.

51. Preti Mario, Vieira-Baptista Pedro, Digesu Giuseppe, Bretschneider Carol, Damaser Margot, Demirkesen Oktay, Heller Debra, Mangir Naside, Marchitelli Claudia. The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynecology and Female Urology: An ICS/ISSVD Best Practice Consensus Document Journal of Lower Genital Tract Disease. 2019 Apr23; 2: 151–160.

52. Stewart WF, Corey R, Herzog AR, Wein A, Norton PA, Payne C. et al. Prevalence of overactive bladder in women: results from the Noble Program. Int Urogynecol J. 2001; 12: S66.

53. Reilly K, Milsom I, Irwin D, Hunskaar S, Kopp Z, Herschorn S. et al. Prevalence of incontinence and overactive bladder: European results from the EPIC study. Eur. Urol. (suppl.) 2006; 5: 116.

54. Malinin V. V., Morozov V. G. Mechanisms of peptide regulation of homeostasis. In the monograph Clinical pharmacology of thymogen, ed. V. S. Smirnov. St. Petersburg, 2003. P. 106. (In Russ.).

55. Pushkar D. Yu., Gamidov S.I., Gomberg V.G., Gural AK, Evidokimov MS, Kasyan GR, Kuzmin IV, Ruzhak GA, Spivak G. G. Vesustim: first results of use in a clinical trial in patients with overactive bladder. Experimental and Clinical Urology 2020; 3: 34–51. (In Russ.).

56. Pushkar D. Yu., Kupriyanov Yu.A., Gamidov S.I., Krivoborodov G. G., Spivak L. G., Al-Shukri S. Kh., Lerman D. M., Gomberg V. G., Bogdan E. N., Shchukin V. L., Chibirov K. Kh., Gelashvili V. V., Gural A. K., Keshishev N. G., Staroselskaya M. A., Bastrikova N. A. Evaluation of the safety and efficacy of the drug Vesustene® in patients with overactive bladder. Journal of Urology. 2022; 3. (In Russ.).

57. Tikhomirova E. V., Balan V. E., Chulkova E. A., Orlova S. A., Zhuravel A. S., Titchenko Yu. P. The experience of using a drug containing the polypeptide of the bladder of cattle in the treatment of patients with hyperacular bladder in perimenopause Russian bulletin of the obstetrician-gynecologist. 2024; 24 (3). (In Russ.).